The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab

@inproceedings{Shima2010TheSO,
  title={The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab},
  author={Yoshihito Shima and Yusuke Kuwahara and Hiroyuki Murota and Shun Kitaba and Mari Kawai and Toru Hirano and Junsuke Arimitsu and Masashi Narazaki and Keisuke Hagihara and Atsushi Ogata and Ichiro Katayama and Ichiro Kawase and Tadamitsu Kishimoto and Toshio Tanaka},
  booktitle={Rheumatology},
  year={2010}
}
OBJECTIVE SSc is an autoimmune disease characterized by fibrosis of the skin and internal organs. Although the aetiology remains uncertain, many reports have suggested that IL-6 is involved in SSc pathogenesis. Tocilizumab, an anti-IL-6 receptor antibody, is an anti-arthritis medicine that works through the blockade of IL-6 functions. To examine the effect of tocilizumab on SSc, we administered tocilizumab to two SSc patients. METHODS Two dcSSc patients were administered tocilizumab at 8 mg… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 66 extracted citations

Hypomethylation and overexpression of ITGAL (CD11a) in CD4+ T cells in systemic sclerosis

Clinical Epigenetics • 2014
View 5 Excerpts
Highly Influenced

References

Publications referenced by this paper.
Showing 1-10 of 14 references

Similar Papers

Loading similar papers…